Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes.

@article{Mimura1994EffectsOA,
  title={Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes.},
  author={Kazuo Mimura and Fumio Umeda and Shinsuke Hiramatsu and Shin-ichi Taniguchi and Yousuke Ono and Nobuo Nakashima and Kisho Kobayashi and Mitsunori Masakado and Yasuhiro Sako and Hajime Nawata},
  journal={Diabetic medicine : a journal of the British Diabetic Association},
  year={1994},
  volume={11 7},
  pages={685-91}
}
The effects of a thiazolidinedione antidiabetic agent (CS-045) on diabetic metabolic abnormalities were studied in a double-blind clinical trial. Fourteen patients with Type 2 diabetes were selected according to study criteria. Eight were treated with oral CS-045 at 400 mg daily, and six were given placebo. A multi-step, hyperinsulinaemic, euglycaemic clamp study, with simultaneous plasma free fatty acid study, and glucagon tolerance test were performed before and after administration of drug… CONTINUE READING